Market revenue in 2023 | USD 42.7 million |
Market revenue in 2030 | USD 65.5 million |
Growth rate | 6.3% (CAGR from 2023 to 2030) |
Largest segment | Biopharmaceuticals |
Fastest growing segment | Biopharmaceuticals |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pharmaceuticals, Biopharmaceuticals |
Key market players worldwide | Boehringer Ingelheim, Novartis AG ADR, Regeneron Pharmaceuticals Inc, Pfizer Inc, Bristol-Myers Squibb Co, Roche Holding AG, UCB SA, Johnson & Johnson, Amgen Inc, AbbVie Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rheumatoid arthritis therapeutics market will help companies and investors design strategic landscapes.
Biopharmaceuticals was the largest segment with a revenue share of 88.76% in 2023. Horizon Databook has segmented the UAE rheumatoid arthritis therapeutics market based on pharmaceuticals, biopharmaceuticals covering the revenue growth of each sub-segment from 2018 to 2030.
The United Arab Emirates (UAE) rheumatoid arthritis therapeutics market has been witnessing gradual growth and evolution, driven by increasing awareness, improved healthcare infrastructure, and advancements in treatment options.
While the prevalence of RA in the UAE is not as high as in some other regions, the demand for effective and innovative treatments remains significant due to the chronic nature of the disease and its impact on patients' quality of life.
One notable trend in the UAE's RA therapeutics market is the adoption of biologic drugs and biosimilars. These advanced therapies offer targeted approaches to managing RA symptoms and have been gaining acceptance among healthcare providers and patients alike.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE rheumatoid arthritis therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into UAE rheumatoid arthritis therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account